ClevelandHeartLab® Know your risk. | Quest Diagnostics™

Report Status: Final

Patient Information	Specimen Information	Client Information

Cardio IQ®

Test Name	Current Result & Risk		Risk/Reference Interval				Historical Result & Risk
	Optimal	Non-Optimal	Optimal	Moderate	High	Units	
INFLAMMATION							
MYELOPEROXIDASE	203		<470	470-539	>=540	pmol/L	

SPECIMEN:

ClevelandHeartLab® Know your risk. | Quest Diagnostics™

Report Status: Final

Patient Information	Specimen Information	Client Information

Reference Range/Comments

Analyte Name	In Range	Out Range	Reference Range	Lab
MYELOPEROXIDASE	**203**		<470 pmol/L	

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Based on a high risk sub-population (N=920) defined as ambulatory stable patients without acute coronary syndrome who underwent elective diagnostic coronary angiography (1) and a reference range study of apparently healthy donors, we have defined the following cut-offs for MPO: A cut-off of <470 pmol/L defines an 'apparently healthy' population at optimal relative risk for a cardiovascular event, 470-539 pmol/L defines a population at moderate relative risk for a cardiovascular event (2-fold increased risk of MACE at 3 years), and > = 540 pmol/L defines a population with a high relative risk for a cardiovascular event. (Reference: 1. Tang et al. Am J Cardiol. 2013; 111:465-470 and personal communication with Tang et al).

SPECIMEN: